SCHEMBL76862

SCHEMBL76862

COC[C@@H](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716147 1.00 HSD17B10 (0.52)
SCHEMBL8437357 1.00 HSD17B10 (0.52)
SCHEMBL415172 1.00
SCHEMBL15183 1.00
Water SCHEMBL9489870 0.97 HSD17B10 (0.50)
Hydrochloric Acid SCHEMBL8061170 0.97
SCHEMBL2013782 0.97
SCHEMBL21403239 0.97
SCHEMBL28488201 0.97
Iodide SCHEMBL30233141 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110862303-A Preparation method of s-metolachlor 上海科利生物医药有限公司 2020-03-06 CN claimed
CN-103922960-B A kind of synthetic method of S-metolachlor ZHEJIANG ZHONGSHAN CHEMICAL GROUP STOCK CO., LTD. (CN) 2015-10-21 CN claimed
CN-103922960-A Synthetic method of S-metolachlor ZHEJIANG ZHONGSHAN CHEMICAL GROUP CO LTD 2014-07-16 CN claimed
WO-2011151434-A1 NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS EUROSCREEN S.A. (BE) 2011-12-08 WO claimed
WO-2001053239-A1 PREPARATION OF OPTICALLY ACTIVE 1-ALKOXY OR ARYLOXY-2-ALKANOL COMPOUNDS PPG-SIPSY SCA (FR) 2001-07-26 WO claimed
CN-122055369-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 CN disclosed
US-20260116891-A1 Oxazepin Derivative TEIJIN PHARMA LTD (JP) 2026-04-30 US disclosed
US-12595265-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2026-04-07 US disclosed
EP-4652164-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-11-26 EP disclosed
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 EP disclosed
US-20250122219-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-04-17 US disclosed
WO-2025080863-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-04-17 WO disclosed
US-6458951-B2 FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION PFIZER INC 2002-10-01 US disclosed
US-20010039271-A1 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction BUNNAGE MARK EDWARD (GB) 2001-11-08 US disclosed
WO-2001053239-A1 PREPARATION OF OPTICALLY ACTIVE 1-ALKOXY OR ARYLOXY-2-ALKANOL COMPOUNDS PPG-SIPSY SCA (FR) 2001-07-26 WO disclosed
US-6251904-B1 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction PFIZER INC. 2001-06-26 US disclosed
CN-1292379-A Preparation method of pyrazolzo [4,3-d] pyrimidine-7-ketone-3-pyridyl sulfonyl compound and its intermediate PFIZER (US) 2001-04-25 CN disclosed
EP-1092720-A2 Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof Pfizer Limited (GB) 2001-04-18 EP disclosed
EP-1073658-A1 PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION PFIZER INC. (US) 2001-02-07 EP disclosed
WO-1999054333-A1 PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION PFIZER INC. (US) 1999-10-28 WO disclosed